Backers included Alger Management and Takeda Pharmaceutical Company, among others.
The company intends to use the funds for research and development, with an emphasis in the fields of central nervous system diseases and disorders, oncology, inflammation, antiinfectives, vaccines, animal health and biodefense, among other fields, and for working capital and general corporate purposes.
Led by Vishwanath R. Lingappa, M.D., Ph.D., Founder, Chief Technology Officer and Co-CEO, Prosetta Biosciences is dedicated to the discovery, development and commercialization of innovative and cost-effective human and animal treatments and therapeutics, based on its assembly machine-targeted systems.
FinSMEs
04/12/2015